$RIGL
RIGEL PHARMACEUTICALS INC

2013 Q2 Form 10-Q Financial Statement

#000110465913060306 Filed on August 06, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2012 Q2
Revenue $1.400M $1.500M
YoY Change -6.67% 275.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.890M $5.460M
YoY Change -10.44% 12.81%
% of Gross Profit
Research & Development $19.39M $20.92M
YoY Change -7.32% 22.29%
% of Gross Profit
Depreciation & Amortization $630.0K $610.0K
YoY Change 3.28% 29.79%
% of Gross Profit
Operating Expenses $19.39M $20.92M
YoY Change -7.32% -4.67%
Operating Profit -$22.89M -$24.88M
YoY Change -8.03%
Interest Expense $120.0K $140.0K
YoY Change -14.29% 75.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$22.77M -$24.74M
YoY Change -7.96% 15.23%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$22.77M -$24.74M
YoY Change -7.96% 15.23%
Net Earnings / Revenue -1626.43% -1649.33%
Basic Earnings Per Share
Diluted Earnings Per Share -$261.3K -$346.2K
COMMON SHARES
Basic Shares Outstanding 87.14M shares 71.45M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $251.6M $202.6M
YoY Change 24.19% -27.41%
Cash & Equivalents $21.90M $26.15M
Short-Term Investments $229.8M $176.5M
Other Short-Term Assets $2.900M $3.700M
YoY Change -21.62% 5.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $254.6M $206.4M
YoY Change 23.35% -26.96%
LONG-TERM ASSETS
Property, Plant & Equipment $5.500M $6.100M
YoY Change -9.84% 17.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.600M $1.900M
YoY Change -15.79% -9.52%
Total Long-Term Assets $7.100M $8.000M
YoY Change -11.25% 9.59%
TOTAL ASSETS
Total Short-Term Assets $254.6M $206.4M
Total Long-Term Assets $7.100M $8.000M
Total Assets $261.7M $214.4M
YoY Change 22.06% -26.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.100M $1.900M
YoY Change 10.53% 26.67%
Accrued Expenses $5.400M $7.200M
YoY Change -25.0% 22.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.500M $9.500M
YoY Change -10.53% 21.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.200M $9.100M
YoY Change -9.89% -3.19%
Total Long-Term Liabilities $8.200M $9.100M
YoY Change -9.89% -3.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.500M $9.500M
Total Long-Term Liabilities $8.200M $9.100M
Total Liabilities $16.60M $18.60M
YoY Change -10.75% 8.14%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $245.1M $195.8M
YoY Change
Total Liabilities & Shareholders Equity $261.7M $214.4M
YoY Change 22.06% -26.04%

Cashflow Statement

Concept 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$22.77M -$24.74M
YoY Change -7.96% 15.23%
Depreciation, Depletion And Amortization $630.0K $610.0K
YoY Change 3.28% 29.79%
Cash From Operating Activities -$21.32M -$20.74M
YoY Change 2.8% 20.79%
INVESTING ACTIVITIES
Capital Expenditures -$250.0K -$820.0K
YoY Change -69.51% 17.14%
Acquisitions
YoY Change
Other Investing Activities $8.460M $24.79M
YoY Change -65.87% -123.33%
Cash From Investing Activities $8.200M $23.97M
YoY Change -65.79% -122.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 820.0K 880.0K
YoY Change -6.82% -99.38%
NET CHANGE
Cash From Operating Activities -21.32M -20.74M
Cash From Investing Activities 8.200M 23.97M
Cash From Financing Activities 820.0K 880.0K
Net Change In Cash -12.30M 4.110M
YoY Change -399.27% -76.16%
FREE CASH FLOW
Cash From Operating Activities -$21.32M -$20.74M
Capital Expenditures -$250.0K -$820.0K
Free Cash Flow -$21.07M -$19.92M
YoY Change 5.77% 20.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11614000 USD
us-gaap Costs And Expenses
CostsAndExpenses
50442000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-48595000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-48192000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
253000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
280000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48342000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47912000 USD
rigl Increase Decrease In Deferred Rent And Other Long Term Liabilities
IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
-52000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-46432000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-44013000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
209436000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
38828000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-65000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
31000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48407000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47881000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1297000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1162000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3540000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
6109000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1141000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-115000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-116000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
424000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
356000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4072000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3598000 USD
rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
-103000 USD
rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
875000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-252000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
72000 USD
rigl Increase Decrease In Deferred Rent And Other Long Term Liabilities
IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
-321000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
224541000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
925000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2392000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
33994000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
50158000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1373000 USD
us-gaap Contracts Revenue
ContractsRevenue
2250000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1282000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
822000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
822000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1373000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18633000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3540000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6109000 USD
CY2013Q2 rigl Cash And Cash Equivalents And Available For Sale Securities Debt Securities Current
CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesCurrent
251641000 USD
CY2012Q4 rigl Cash And Cash Equivalents And Available For Sale Securities Debt Securities Current
CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesCurrent
298241000 USD
CY2013Q2 rigl Cash Equivalents And Available For Sale Securities Amortized Cost
CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
243655000 USD
CY2013Q2 rigl Cash Equivalents And Available For Sale Securities Gross Unrealized Gain
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain
79000 USD
CY2013Q2 rigl Cash Equivalents And Available For Sale Securities Gross Unrealized Losses
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses
62000 USD
CY2013Q2 rigl Cash Equivalents And Available For Sale Securities Debt Securities Unrealized Gain Loss Fair Value Disclosure
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesUnrealizedGainLossFairValueDisclosure
243672000 USD
CY2012Q4 rigl Cash Equivalents And Available For Sale Securities Amortized Cost
CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
273972000 USD
CY2012Q4 rigl Cash Equivalents And Available For Sale Securities Gross Unrealized Gain
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain
135000 USD
CY2012Q4 rigl Cash Equivalents And Available For Sale Securities Gross Unrealized Losses
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses
53000 USD
CY2012Q4 rigl Cash Equivalents And Available For Sale Securities Debt Securities Unrealized Gain Loss Fair Value Disclosure
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesUnrealizedGainLossFairValueDisclosure
274054000 USD
CY2013Q2 rigl Cash Equivalents And Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
CashEquivalentsAndAvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
205716000 USD
CY2013Q2 rigl Cash Equivalents And Available For Sale Securities Debt Maturities Rolling Year Two Fair Value
CashEquivalentsAndAvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoFairValue
37956000 USD
rigl Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P235D
rigl Available For Sale Securities Debt Securities Current Stated Maturity Period May Be Greater Than This Period
AvailableForSaleSecuritiesDebtSecuritiesCurrentStatedMaturityPeriodMayBeGreaterThanThisPeriod
P1Y
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-11616000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
7518000 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26151000 USD
CY2013Q2 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions
44 item
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
87144000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71440000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16034000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14066000 shares
CY2013Q2 us-gaap Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2
0 USD
CY2012Q4 us-gaap Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2
0 USD
dei Amendment Flag
AmendmentFlag
false
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16116000 shares
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14100000 shares
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1747000 USD
CY2013Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
98600000 USD
CY2013Q2 us-gaap Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2
62000 USD
CY2013Q2 us-gaap Contracts Revenue
ContractsRevenue
1400000 USD
CY2012Q2 us-gaap Contracts Revenue
ContractsRevenue
1500000 USD
us-gaap Contracts Revenue
ContractsRevenue
1400000 USD
CY2013Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
19393000 USD
CY2012Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
20924000 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4892000 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5458000 USD
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
24285000 USD
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
26382000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22885000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-24882000 USD
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
117000 USD
CY2012Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
144000 USD
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22768000 USD
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24738000 USD
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
87147000 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71458000 shares
CY2013Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-61000 USD
CY2012Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
12000 USD
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24726000 USD
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22829000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Nature of Operations</font></b></p> <p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;">&#160;</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">We were incorporated in the state of Delaware on June&#160;14, 1996. We are engaged in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> </div>
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">2.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Basis of Presentation</font></b></p> <p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;">&#160;</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Our accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP), for interim financial information and pursuant to the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet at December&#160;31, 2012 has been derived from audited financial statements at that date, but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2012.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> </div>
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
277091000 USD

Files In Submission

Name View Source Status
0001104659-13-060306-index-headers.html Edgar Link pending
0001104659-13-060306-index.html Edgar Link pending
0001104659-13-060306.txt Edgar Link pending
0001104659-13-060306-xbrl.zip Edgar Link pending
a13-13767_110q.htm Edgar Link pending
a13-13767_1ex31d1.htm Edgar Link pending
a13-13767_1ex31d2.htm Edgar Link pending
a13-13767_1ex32d1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
rigl-20130630.xml Edgar Link completed
rigl-20130630.xsd Edgar Link pending
rigl-20130630_cal.xml Edgar Link unprocessable
rigl-20130630_def.xml Edgar Link unprocessable
rigl-20130630_lab.xml Edgar Link unprocessable
rigl-20130630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending